Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Langdon

Showing results (81-90 of 180) with videos related to

Pageof 18
Sort By:
British Journal of Cancer|June 1, 1982
N-methylformamide: antitumour activity and metabolism in miceA Gescher, N W Gibson, J A Hickman, et al.
Seminars in Oncology|February 1, 1991
Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimensD Raghavan, B Pearson, W H Watt, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymesA D Ramage, S P Langdon, A A Ritchie, et al.
International Journal of Cancer|June 22, 1995
c-erbB growth-factor-receptor proteins in ovarian tumoursB J Simpson, H A Phillips, A M Lessells, et al.
Veterinary Journal (London, England : 1997)|September 11, 2018
Implantable biosensors and their contribution to the future of precision medicineM Gray, J Meehan, C Ward, et al.
British Journal of Cancer|January 1, 1997
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in ScotlandP Mullen, W R Miller, J Mackay, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1985
N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapyS P Langdon, J A Hickman, A Gescher, et al.
Biochemical Pharmacology|May 26, 1995
Processing of the neuropeptide growth factor antagonist [Arg6, D-Trp7.9, NmePhe8]-substance P (6-11) by a small cell lung cancer cell line (H69)J Cummings, A J MacLellan, S P Langdon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenograftsK Breistøl, H R Hendriks, D P Berger, et al.
Current Topics in Microbiology and Immunology|March 13, 2019
Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and TreatmentCarol Ward, James Meehan, Mark Gray, et al.
Pageof 18

Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Cancer|June 1, 1982
N-methylformamide: antitumour activity and metabolism in miceA Gescher, N W Gibson, J A Hickman, et al.
Seminars in Oncology|February 1, 1991
Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimensD Raghavan, B Pearson, W H Watt, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1995
Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymesA D Ramage, S P Langdon, A A Ritchie, et al.
International Journal of Cancer|June 22, 1995
c-erbB growth-factor-receptor proteins in ovarian tumoursB J Simpson, H A Phillips, A M Lessells, et al.
Veterinary Journal (London, England : 1997)|September 11, 2018
Implantable biosensors and their contribution to the future of precision medicineM Gray, J Meehan, C Ward, et al.
British Journal of Cancer|January 1, 1997
BRCA1 5382insC mutation in sporadic and familial breast and ovarian carcinoma in ScotlandP Mullen, W R Miller, J Mackay, et al.
European Journal of Cancer & Clinical Oncology|June 1, 1985
N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapyS P Langdon, J A Hickman, A Gescher, et al.
Biochemical Pharmacology|May 26, 1995
Processing of the neuropeptide growth factor antagonist [Arg6, D-Trp7.9, NmePhe8]-substance P (6-11) by a small cell lung cancer cell line (H69)J Cummings, A J MacLellan, S P Langdon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 20, 1999
The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenograftsK Breistøl, H R Hendriks, D P Berger, et al.
Current Topics in Microbiology and Immunology|March 13, 2019
Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and TreatmentCarol Ward, James Meehan, Mark Gray, et al.
Pageof 18